ReviewFrontiers in cellular and infection microbiology2022
The mechanism of berberine alleviating metabolic disorder based on gut microbiome.
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The Integrative Role of Berberine in Gut Microbiota Modulation and Cardiometabolic Outcomes: A Systematic Review of Randomised Clinical Trials.Nutrients · 2026Pooled it
- Mapping the global research output of Traditional Chinese Medicine in the treatment of metabolic dysfunction-associated steatotic liver disease: a comprehensive bibliometric analysis based on multiple databases (2000-2025).Frontiers in medicine · 2026Pooled it
- Pooled it
- Time-dose response and mechanistic specificity of berberine in renal fibrosis from a multi-model integration perspective: a systematic review and meta-analysis on animal models.Frontiers in pharmacology · 2025Pooled it
- Article
- Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metabolic and Anti-Inflammatory Effects of Berberine-Rationale for Its Therapeutic Potential in Polycystic Ovary Syndrome.International journal of molecular sciences · 2026Review
- Defined Natural Products as Adjunctive Therapies: Evidence-Gated Polypharmacology Across Molecular Targets, Human Exposure, Clinical Signals, and Safety Boundaries.International journal of molecular sciences · 2026Review
- Effects of Macleaya Cordata Extract on LPS-Induced Intestinal Inflammation and Diarrhea via Modulation of Gut Microbiota.Animals : an open access journal from MDPI · 2026Article
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- Gut Microbiota, Diet and Lipid Metabolism in Adolescents with NAFLD and Their Role in Preventive Strategies.International journal of molecular sciences · 2026Review
- Berberine Attenuates Glucocorticoid-Induced Bone Loss in Mice: Associated with the Gut Microbiota-Glycerophospholipid Metabolic Axis.Foods (Basel, Switzerland) · 2026Article
- Carrier-free supramolecular architectonics of quercetinMaterials today. Bio · 2026Article
- Engineered prebiotic microcapsules Co-Encapsulating berberine and curcumin Elicit multi-synergistic therapy for ulcerative colitis.Materials today. Bio · 2026Article
- Engineered chitosan/HP-β-CD hydrogel for targeted co-delivery of curcumin and berberine for the treatment of ulcerative colitis.Journal of biological engineering · 2026Article
- Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026Review
- Berberine Ameliorates Diabetic Kidney Disease by Modulating Macrophage Polarization via Inhibiting IL-17A Signaling.Journal of inflammation research · 2026Article
- Research progress on the relationship and mechanisms of obesity, gut microbiota, and natural medicines.Frontiers in endocrinology · 2026Review
- Holistic concept guided quality control of traditional Chinese medicines for optimizing bioavailability.Chinese medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With socioeconomic advances and improved living standards, metabolic syndrome has increasingly come into the attention. In recent decades, a growing number of studies have shown that the gut microbiome and its metabolites are closely related to the occurrence and development of many metabolic diseases, and play an important role that cannot be ignored, for instance, obesity, type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease and others. The correlation between gut microbiota and metabolic disorder has been widely recognized. Metabolic disorder could cause imbalance in gut microbiota, and disturbance of gut microbiota could aggravate metabolic disorder as well. Berberine (BBR), as a natural ingredient, plays an important role in the treatment of metabolic disorder. Studies have shown that BBR can alleviate the pathological conditions of metabolic disorders, and the mechanism is related to the regulation of gut microbiota: gut microbiota could regulate the absorption and utilization of berberine in the body; meanwhile, the structure and function of gut microbiota also changed after intervention by berberine. Therefore, we summarize relevant mechanism research, including the expressions of nitroreductases-producing bacteria to promote the absorption and utilization of berberine, strengthening intestinal barrier function, ameliorating inflammation regulating bile acid signal pathway and axis of bacteria-gut-brain. The aim of our study is to clarify the therapeutic characteristics of berberine further and provide the theoretical basis for the regulation of metabolic disorder from the perspective of gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.